
Shocking Lab Results Medical Workers Can't Forget
Medical workers are the unsung heroes of our society, and they often deal with some truly bizarre, shocking, and traumatic things on the job. Sometimes, their stories sound too wild to be true.
Throughout the COVID-19 pandemic, nurses, doctors, and anyone working in the medical field were at the forefront of a global pandemic that claimed millions of lives. But even outside of dire circumstances, their job involves witnessing some truly shocking stuff.
During a recent Reddit deep dive, I came across this post in the r/AskReddit sub from one user who asked medical workers to share "the craziest lab result you've seen in a patient." Some of these entries are truly terrifying.
"Sent a patient for an ambulatory sleep study when he was referred to us for suspected sleep apnea. He was very tired and apathetic when he came in. His test came back with an Apnea-Hypopnea Index of 127, with the longest apnea episode lasting 77 seconds, essentially meaning he was stopping 127 times every hour."
"Called him back in urgently to start a CPAP trial, moved to VPAP, and last I had seen him, he was happy, cheerful, and about 35 kilograms lighter than when we initially saw him."–u/HaruDolly
"Older woman with a pulse rate of 8. I figured the pulse oximeter was sh*tting the bed, as they often do, so I told my coworker to take it off the patient and put it on me, to check if it was the machine acting weird. The coworker put the pulse oximeter on me, and it showed a normal, healthy pulse rate almost immediately. My coworker and I looked at each other, looked at the patient, looked at each other again, and just went 'oh fuck.'"
–u/Mysterious_Bag_9061
"Not a lab, but I had a patient walk in for an Electroencephalogram (EEG). We chatted the whole time. Super nice. Started the EEG. They were having a seizure every 30-40 seconds and had no idea. They drove there."
–u/Nomofricks
"Blood pressure of 280/186 on a pregnant patient in the field (I'm an EMT). Terrifying."
"As a lab tech, I've seen quite a few. The highest glucose I've seen was 1750, the highest accurate potassium was 7.9 (the rule of thumb is 8, and you're big dead, hemolyzed samples make it shoot up, so it's likely not real, but that one WAS). I learned our lactic acid analyzer only goes up to 40; that guy unfortunately didn't live long. I've seen a urine sample with so many crystals, I couldn't see anything else. My most recent was an 89-year-old man with what appeared to be a LOT of very healthy-looking sperm in his urine sample. I was shocked at the quality and quantity of them."
"I had a 10-year-old boy come into the emergency department for his diabetes. The finger-prick result was so high it wouldn't give a measure, which means it was ridiculously high. Parents were saying, 'He's always thirsty, but we only give him orange juice that has no added sugar. And McDonald's shakes.' For anyone not aware, both these things may as well be pure sugar for someone with diabetes."
–u/Binda33
"Not a specific lab result, but one time I had to process a blood sample where the plasma looked like strawberry Go-Gurt. Ideally, it would be almost clear."
–u/Popular_Emu1723
"Internal medicine resident here. Our clinic often has patients who get lost to follow up. A patient came in just under two years after his last appointment, where it was revealed he had a ferritin of 1. I repeat, ferritin of 1. Poor guy also had hemorrhoids and said he was bleeding every day; continuous fatigue — no kidding! Nothing to replenish your hemoglobin stores! The crummy part is that the ferritin was a lab from a while ago, and he never followed up for intervention; we're on track now, though."
"As a lab scientist in Australia, brown snake envenomation always provides interesting results. Had one 22-year-old male who went into Disseminated Intravascular Coagulation following a brown snake bite and died with a haemoglobin of 22. He was a Jehovah's Witness and refused a transfusion."
–u/thumpingcoffee
"The record WBC (white blood cell) count I've seen on admission was 185,000. (Acute Myeloid Leukemia)."
"A sodium of 555. Yes, you read it right. We looked at him. He replied, 'I don't feel so good,' and dropped dead. I'll never forget it as long as I live."
"Reading a bone marrow aspirate and found what ended up being Histoplasma capsulatum. Everyone related to hematology was in my office that day. Many extra slides were pulled and stained for personal collections."
–u/hopingforchange
"A tortuous, herniating stroke. The brain was twisting clockwise from the left temporal region and herniating through the foramen magnum. Symptoms were headache and dizziness for 45 minutes."
"A genetic test that came back XY on a patient with a clear vulva and no penis. We sent another blood test to a different lab to confirm there was no error. There was no error. The child was male, but had a vulva and no penis. Gender is truly a spectrum."
–u/WhatsInAName8879660
"I was the doctor covering a psychiatric hospital on the night shift. At the tail end of the shift, around 6 a.m., nurses from one of the Old Age wards called me saying one of their patients had been complaining of chest pain since midnight, but they didn't want to reach out at that time as they didn't think it was so serious to disturb me."
"Got a call from the lab tech that my patient had 'Blue-Green crystals of death.' The tech said that when those show up, death is usually imminent. The patient passed about an hour later."
"I'm not a med tech, but I am a phlebotomist. I had a child with blood that was so thin, it looked like a Halloween prop. When I dropped off the sample, the med tech did not believe me when I told them it was real and not just me covering up some sort of mess up. I don't know what that child's hemoglobin was, but it was scary low. Low enough that the same med tech was surprised they were alive. I have never seen blood so thin before in my 11 years on this job. It was red-tinted water."
–u/zombae788
"Worked in hospice for a time. Joint visit with the RN. Patient's pulse oximeter was 18%...awake, completely oriented, talkative — not short of breath or any other symptoms. The highest it went. The entire visit was 25%...we kept trying it on ourselves, different fingers. The nurse even tried toe readings on us, which were all normal. We straight up told the patient and family...we aren't sure how you are awake and talking to us, but we don't think you'll be with us a whole lot longer. Patient and family were extremely understanding — lived another 18 hours talking and visiting with family, ultimately passing in their sleep."
"Heart rate of 0 when a man was sitting up and talking, then after a few seconds of 0, he paused and stared, we were dumbfounded, figuring the leads were bad, then after 17 seconds, he came back and finished his sentence, Heart rate back to normal."
–u/cporterriley

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
18 minutes ago
- Newsweek
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.
Yahoo
33 minutes ago
- Yahoo
Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving with innovations like phage display and AI-driven design. The market is booming across North America, Europe, and Asia-Pacific, driven by personalized medicine and rapid advancements in antibody discovery technologies. Antibody Discovery Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Antibody Discovery - Global Strategic Business Report" has been added to global market for Antibody Discovery was valued at US$1.9 Billion in 2024 and is projected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Antibody Discovery market. Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase - encompassing target identification, antibody generation, screening, and lead optimization - is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques - ranging from chimerization to full deimmunization - are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific - especially China, South Korea, and Japan - is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases - including rheumatoid arthritis, psoriasis, and Crohn's disease - also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer's, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across Is Fueling the Growth of the Global Antibody Discovery Market?The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market - such as trastuzumab, adalimumab, and pembrolizumab - which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges - can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?Report ScopeThe report analyzes the Antibody Discovery market, presented in terms of market value (US$ Thousand). The analysis covers the key segments outlined Antibody Type (Monoclonal, Polyclonal, Other Antibody Types) Service (Phage Display, Hybridoma, Other Services) End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses) Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibody segment, which is expected to reach US$2 Billion by 2030 with a CAGR of a 9.3%. The Polyclonal Antibody segment is also set to grow at 10.9% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $500.0 Million in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $530.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam, AbCellera Biologics, Ablexis, Adimab, Akeso Biopharma and more. Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities. Key Attributes: Report Attribute Details No. of Pages 224 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.9 Billion Forecasted Market Value (USD) by 2030 $3.3 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW World Market Trajectories Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines Transgenic Animal Models Expand the Scope of Novel Antibody Generation Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery Data Integration Across Platforms Enhances Efficiency in Antibody Optimization Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery FOCUS ON SELECT PLAYERSSome of the 41 companies featured in this Antibody Discovery market report include: Abcam AbCellera Biologics Inc. Ablexis Adimab Akeso Biopharma Biocytogen Pharmaceuticals Co., Ltd. Bruker Corporation Charles River Laboratories ChemPartner Creative Biolabs Danaher Corporation Eurofins Scientific Evotec SE FairJourney Biologics Genmab GenScript Biotech Corporation Harbour BioMed Icosagen AS ImmunoPrecise Antibodies Ltd. Isogenica Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Discovery Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
3 hours ago
- Business Insider
Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19
Moderna (MRNA) announced that the U.S. Food and Drug Administration, FDA, has approved mNEXSPIKE, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' said Stephane Bancel, Chief Executive Officer of Moderna. 'COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health.' Confident Investing Starts Here: